Home /

The psychedelic revolution is coming. Psychiatry may never be the same

By Andrew Jacobs
New York Times·
13 mins to read

Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.

It's been a long, strange trip in the four decades since Rick Doblin, a pioneering psychedelics researcher, dropped his first hit of acid in college and decided to dedicate his life to the healing powers of mind-altering compounds. Even as anti-drug campaigns led to the criminalisation of Ecstasy,

Save